# Comprehensive first–trimester targeted metabolomics for early prediction and understanding of GDM pathophysiology

**Authors:** Patrycja Mojsak, Adrian Godlewski, Krzysztof Sołowiej, Agieszka Kulczynska–Przybik, Sandra Chmielewska, Barbara Mroczko, Małgorzata Szelachowska, Adam Krętowski, Michał Ciborowski

PMC · DOI: 10.3389/fmolb.2026.1760710 · Frontiers in Molecular Biosciences · 2026-02-16

## TL;DR

This study uses metabolomics to identify early signs of gestational diabetes in the first trimester, offering potential for early diagnosis and understanding of the condition.

## Contribution

The study presents the first large-scale first-trimester metabolomic analysis for early prediction and mechanistic understanding of GDM.

## Key findings

- A prognostic panel of metabolites accurately predicted GDM with an AUC of 0.934.
- A diagnostic panel detected early signs of carbohydrate metabolism issues with an AUC of 0.821.
- Women with normal fasting glucose but later GDM showed significant lipid alterations.

## Abstract

Gestational diabetes mellitus (GDM) is among the most common metabolic disorders during pregnancy, and early detection is key to reducing complications for both mother and child. Mass spectrometry–based metabolomics enables detailed metabolite profiling, offering opportunities not only for early diagnosis and risk prediction but also for understanding the pathophysiological mechanisms that drive the development of GDM.

For the first time, an analysis of such a large number of metabolites was conducted: over 1,000 metabolites across 39 biochemical classes, including 912 lipids and 107 small molecules, were measured in first-trimester plasma from women with abnormal or normal fasting plasma glucose who later developed GDM, as well as from controls with normal glucose tolerance. Statistical analyses included Kruskal–Wallis ANOVA with Conover–Iman post hoc tests, Wilcoxon signed-rank tests for longitudinal changes, and ROC analysis to assess predictive and diagnostic performance. Spearman’s rank correlations were used to examine relationships between metabolites and clinical parameters.

Distinct metabolic signatures in the first trimester were associated with later GDM development. A prognostic panel, including TG (18:1_36:6), Hex2Cer(d18:1/14:0), valine, PS(36:1), TG (17:2_36:3), p-cresol sulfate, and PC(O–42:4), accurately predicted GDM (AUC = 0.934). A diagnostic panel comprising PE (P–18:0/22:4), glycine-conjugated cholic acid, LPC (20:3), carnitine esters, and arginine detected early signs of carbohydrate metabolism issues (AUC = 0.821). Women with normal fasting glucose who later developed GDM exhibited significant lipid alterations, whereas those with early fasting irregularities showed a partially GDM-like profile. Correlation analyses revealed distinct inflammatory and hormonal networks, with TNF–α–induced lipid remodelling linked to early dysglycaemia.

First-trimester metabolomic signatures hold significant promise for early prediction, diagnosis, and understanding of GDM, enabling personalised risk assessment and timely intervention during pregnancy.

## Linked entities

- **Chemicals:** valine (PubChem CID 1182), PS(36:1) (PubChem CID 52925216), p-cresol sulfate (PubChem CID 4615423), PC(O–42:4) (PubChem CID 164458670), PE (P–18:0/22:4) (PubChem CID 52925094), LPC (20:3) (PubChem CID 52924055), arginine (PubChem CID 232)
- **Diseases:** gestational diabetes mellitus (MONDO:0005406)

## Full-text entities

- **Genes:** PLA2G1B (phospholipase A2 group IB) [NCBI Gene 5319] {aka PLA2, PLA2A, PPLA2}, PRKAA1 (protein kinase AMP-activated catalytic subunit alpha 1) [NCBI Gene 5562] {aka AMPK, AMPK alpha 1, AMPKa1}, PC (pyruvate carboxylase) [NCBI Gene 5091] {aka PCB}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, PYY (peptide YY) [NCBI Gene 5697] {aka PYY-I, PYY1}, PSS (Potocki-Shaffer syndrome) [NCBI Gene 780904], NAMPT (nicotinamide phosphoribosyltransferase) [NCBI Gene 10135] {aka 1110035O14Rik, PBEF, PBEF1, VF, VISFATIN}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, LEP (leptin) [NCBI Gene 3952] {aka LEPD, OB, OBS}, TCF20 (transcription factor 20) [NCBI Gene 6942] {aka AR1, DDVIBA, SPBP, TCF-20}, GNAT3 (G protein subunit alpha transducin 3) [NCBI Gene 346562] {aka GDCA, HG1E}, GPLD1 (glycosylphosphatidylinositol specific phospholipase D1) [NCBI Gene 2822] {aka GPIPLD, GPIPLDM, PIGPLD, PIGPLD1, PLD}, SLC25A20 (solute carrier family 25 member 20) [NCBI Gene 788] {aka CAC, CACT}, AAAS (aladin WD repeat nucleoporin) [NCBI Gene 8086] {aka AAA, AAASb, ADRACALA, ADRACALIN, ALADIN, GL003}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, INSR (insulin receptor) [NCBI Gene 3643] {aka CD220, HHF5}, VIP (vasoactive intestinal peptide) [NCBI Gene 7432] {aka PHM27}
- **Diseases:** Insulin Resistance (MESH:D007333), vascular dysfunction (MESH:D002561), placental dysfunction (MESH:D010922), preterm birth (MESH:D047928), impaired fasting glucose (MESH:D007003), impaired glucose regulation (MESH:C565631), shoulder dystocia (MESH:D000080883), SCAD deficiency (MESH:D007153), CACT deficiency (MESH:C562812), lipid (MESH:D011017), NGT (MESH:D018149), beta-cell dysfunction (MESH:D007340), carbohydrate (MESH:C562602), PKU (MESH:D010661), T2DM (MESH:D003924), impaired glucose metabolism (MESH:D044882), preeclampsia (MESH:D011225), diabetes (MESH:D003920), endothelial dysfunction (MESH:D014652), macrosomia (MESH:D005320), mitochondrial dysfunction (MESH:D028361), carbohydrate metabolism (MESH:D002239), metabolic syndrome (MESH:D024821), hyperglycemia (MESH:D006943), inflammation (MESH:D007249), mitochondrial dysregulation (MESH:D021081), metabolic disorders (MESH:D008659), GCTs (MESH:D013736), GDM (MESH:D016640), NBS (MESH:D049932), obese (MESH:D009765), hepatic steatosis (MESH:D005234)
- **Chemicals:** phosphatidylserine (MESH:D010718), MUFA (MESH:D005229), PC (MESH:D010713), fatty acid (MESH:D005227), Arg (MESH:D001120), carbohydrate (MESH:D002241), serine (MESH:D012694), Phe (MESH:D010649), acylcarnitine (MESH:C116917), cholesterol esters (MESH:D002788), Amino acids (MESH:D000596), homocysteine (MESH:D006710), lysophospholipids (MESH:D008246), carnitine (MESH:D002331), PUFA (MESH:D005231), TG (MESH:D013866), pyridine (MESH:C023666), dihexosylceramide (MESH:C012905), sphingomyelin (MESH:D013109), bile acid (MESH:D001647), PE (MESH:C483858), Hex2Cer (-), phenyl isothiocyanate (MESH:C005441), monoacylglycerol (MESH:D050178), folate (MESH:D005492), glucose (MESH:D005947), creatinine (MESH:D003404), tryptophan (MESH:D014364), diacylglycerols (MESH:D004075), acetylcarnitine (MESH:D000108), Plasmalogens (MESH:D010955), sphingolipid (MESH:D013107), lysophosphatidylcholine (MESH:D008244), sterol (MESH:D013261), ammonium acetate (MESH:C018824), very long-chain fatty acid (MESH:C017364), LPS (MESH:D008070), lipid (MESH:D008055), Cys (MESH:D003545), glycodeoxycholic acid (MESH:D006002), PEs (MESH:D010714), carbon (MESH:D002244), fructosamine (MESH:D019270), CA (MESH:D019826), cortisone (MESH:D003348), ALA (MESH:D000409), Triacylglycerols (MESH:D014280), p-Cresol-sulphate (MESH:C408690), isoleucine (MESH:D007532), sulphate (MESH:D013431), AABA (MESH:C012223), O (MESH:D010100), aromatic amino acids (MESH:D024322), acid (MESH:D000143), glycerophospholipids (MESH:D020404), P (MESH:D010758), PI (MESH:D010716), methanol (MESH:D000432), methionine (MESH:D008715), glycine (MESH:D005998)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12950703/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12950703/full.md

## References

70 references — full list in the complete paper: https://tomesphere.com/paper/PMC12950703/full.md

---
Source: https://tomesphere.com/paper/PMC12950703